CanSino Biologics Inc (CanSinoBIO), a Chinese biopharmaceutical company that is developing a COVID-19 vaccine candidate, plans to raise a total of 5.2 billion yuan ($743 million) in an initial public offering (IPO) on Shanghai’s Nasdaq-style STAR Market, according to a company filing on Thursday.
Continue reading this premium story with a subscription to DealStreetAsia.
SubscribeAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
